Abstract: The invention relates, in one aspect, to a tablet having an internal core and external coating, both comprising melatonin and separated by an internal coating which does not comprise melatonin. The tablet is useful as a medicinal product, dietetic or food supplements for the treatment or as adjunctive therapy in sleep disorders.
Abstract: A controlled release melatonin tablet having a slow release nucleus of melatonin, hydroxypropyl methylcellulose, a lubricant, a volume excipient and a glidant, wherein 95% of the melatonin is released within 5 hours in an oscillating tray containing gastric/intestinal juice at 37° C. and a fast release cortex coating on said nucleus of melatonin, hydroxypropyl methylcellulose and a volume excipient, wherein at least 95% of the melatonin is released within 10 minutes in an oscillating tray containing gastric/intestinal juice at 37° C.
Abstract: New controlled-release formulations containing tryptophan and/or its metabolites are described, as well as the process to obtain them in tablet forms suitable for oral administration in the treatment of pathologies or conditions related to serotonin deficiency in the Nervous System. The formulations are comprised in double-layer tablets, one layer containing 5-hyrohytryptophan released rapidly (phase “fast), the other layer containing tryptophan or 5-hydroxytryptophan, progressively released (“retarded”). The finished product is characterized by optimal differential release profile under physiological conditions. In all cases the release kinetics obtained is accurately time- and concentration-controlled, therefore avoiding fortuitous release of the active ingredients, and in clinical setting is free of undesirable side effects.
Abstract: Compositions containing compounds with adrenergic activity and an extract of Crataegus standardized in flavonoids, combined with an extract of Gingko biloba standardized in flavonglucosides in appropriate weight ratios are suitable for pharmaceutical administration or as food supplements for the treatment of weight loss and obesity in humans. The formulations are appropriate for the administration of the active ingredients in a form that increases patient compliance and the efficacy of the therapeutic or dietary intervention, but reduces the untoward effects of the compounds with adrenergic activity.